Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

Loosli, TomBolton-Moore, CarolynBuzaalirwa, LydiaByakwaga, HelenÇelikağ, İpekChimbetete, CleophasEbasone, Peter V.Giandhari, JenniferHan, NuriHuwa, JacquelineKasozi, CharlesMafoua, AdolpheMessou, EugèneMinga, AlbertMuula, GuyMuyindike, WinnieNdala, Arcel C. M.Sauermann, MamathaSemeere, AggreySingh, LavanyaKouyos, Roger D.Lessells, RichardEgger, Matthias2025-09-172025-May-210.1093/cid/ciaf204https://pubs.cidrz.org/handle/123456789/12005Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.https://pubmed.ncbi.nlm.nih.gov/40391923/